Pegsunercept
Pegsunercept
Pegsunercept (pronunciation: peg-sun-er-cept) is a type of biopharmaceutical drug that was developed for the treatment of certain autoimmune diseases and cancers.
Etymology
The name "Pegsunercept" is derived from the combination of "peg", short for pegylated, a process that increases the drug's stability and half-life, and "sunercept", a reference to the drug's function as a receptor antagonist.
Function
Pegsunercept works by binding to and inhibiting the activity of a specific type of cytokine known as tumor necrosis factor (TNF). TNF is a protein that plays a key role in promoting inflammation and cell death, processes that are overactive in certain diseases. By blocking TNF, Pegsunercept can help to reduce symptoms and slow disease progression.
Clinical Use
Pegsunercept has been studied for use in a variety of conditions, including rheumatoid arthritis, psoriasis, and certain types of cancer. However, it is not currently approved for use in any country.
Side Effects
Like all drugs, Pegsunercept can cause side effects. These may include nausea, fatigue, and injection site reactions. In rare cases, it may also cause serious side effects such as infections, heart failure, and neurological disorders.
Related Terms
- Biopharmaceutical
- Autoimmune disease
- Cancer
- Pegylation
- Cytokine
- Tumor necrosis factor
- Rheumatoid arthritis
- Psoriasis
- Nausea
- Fatigue
- Injection site reaction
- Infection
- Heart failure
- Neurological disorder
External links
- Medical encyclopedia article on Pegsunercept
- Wikipedia's article - Pegsunercept
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski